Tumor Antigen by Immunoassay - CA 19-9 — NCD 142 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 142, the national coverage determination governing CA 19-9 tumor antigen testing by immunoassay, effective March 7, 2026. Here's what billing teams need to know.

This update to the CMS CA 19-9 coverage policy draws a hard line between covered and non-covered uses of this test. The policy does not list specific CPT or HCPCS codes in the current document — but the coverage criteria are specific enough that your billing team needs to review every CA 19-9 claim against the indications below before the effective date of March 7, 2026.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Tumor Antigen by Immunoassay — CA 19-9
Policy Code	NCD 142
Change Type	Modified
Effective Date	2026-03-07
Impact Level	Medium
Specialties Affected	Clinical laboratory, oncology, gastroenterology, hepatobiliary surgery
Key Action	Audit CA 19-9 claims to confirm the patient has an established diagnosis of pancreatic or biliary ductal carcinoma — not a suspected or symptomatic presentation

---

CMS CA 19-9 Coverage Criteria and Medical Necessity Requirements 2026

The CMS CA 19-9 coverage policy covers one specific use case: monitoring patients who already carry an established diagnosis of pancreatic carcinoma or biliary ductal carcinoma. That's it.

CA 19-9 is a carbohydrate antigen. When elevated, serum levels can reflect tumor size and grade. That clinical utility is real — but CMS limits reimbursement to a narrow window of use, and NCD 142 makes that window explicit.

What Medical Necessity Looks Like Under NCD 142

For a CA 19-9 test to meet medical necessity under this coverage policy, two things must be true. First, the patient has a confirmed, established diagnosis of pancreatic or biliary ductal carcinoma. Second, the test is ordered to monitor response to treatment or to assess for recurrent disease after surgical therapy.

Order frequency matters here too. The policy states the test "may be ordered at times necessary" — which means frequency should align with treatment cycles. Ordering the test on a fixed monthly schedule, regardless of where the patient is in their treatment course, creates claim denial risk. Tie the order to a specific clinical decision point: a new treatment cycle, a post-surgical follow-up window, or a documented concern about recurrence.

Prior authorization is not explicitly required under NCD 142 — but documentation requirements are effectively the same burden. If a Medicare Administrative Contractor audits these claims, they'll want to see the established diagnosis, the treatment context, and the clinical rationale for each order.

---

CMS CA 19-9 Exclusions and Non-Covered Indications

This is where NCD 142 bites practices that aren't paying attention.

The policy explicitly excludes CA 19-9 testing for patients who show signs or symptoms suggestive of malignancy but don't yet have a confirmed diagnosis. That's a workup use case — and CMS does not cover it under NCD 142.

The Diagnostic Trap

Your ordering physician suspects pancreatic cancer. The patient has weight loss, jaundice, and elevated liver enzymes. They order CA 19-9 as part of the diagnostic workup. That claim will not survive scrutiny under this coverage policy.

The policy is unambiguous: "The test is not indicated for diagnosing these two diseases." Pancreatic and biliary ductal carcinoma are the two diseases. If the diagnosis isn't confirmed yet, the test is not covered under NCD 142.

This is a common revenue cycle blind spot. Oncology workups generate a lot of tumor marker orders. The clinical logic makes sense — you're trying to establish a baseline or support a diagnosis. But Medicare draws the line at monitoring, not diagnosis. Your billing guidelines need to reflect that distinction clearly.

Signs and Symptoms Exclusion

The policy also bars coverage when the test is ordered to evaluate patients with "signs or symptoms suggestive of malignancy." This is broader than the diagnostic exclusion above. Even if the physician isn't trying to diagnose cancer — just evaluate a symptom cluster — the test won't be covered if there's no confirmed diagnosis in the record.

Train your clinical documentation team to distinguish between "established diagnosis + monitoring" and "suspected malignancy + workup." These two clinical scenarios look similar at the point of care but produce very different coverage outcomes.

---

Coverage Indications at a Glance

---

CMS CA 19-9 Billing Guidelines and Action Items 2026

The effective date for this modified policy is March 7, 2026. Here's what your team needs to do before and after that date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for CA 19-9 Tumor Antigen Testing Under NCD 142

The current version of NCD 142 does not list specific CPT, HCPCS, or ICD-10 codes. CMS references a quarterly Covered Code List for this policy — check the CMS source document directly for the most current code list, as these are updated on a rolling basis.

The absence of codes in the policy document itself is notable. It means your CA 19-9 billing relies entirely on the indication and documentation criteria above, not on code-level coverage rules. That puts more weight on your documentation and diagnosis coding — and more exposure if either is weak.

For billing reference, CA 19-9 immunoassay tests are typically reported using lab-specific CPT codes for quantitative immunoassay methods. Your laboratory billing team should confirm the correct code for their methodology against CMS's Covered Code List. Do not assume coverage based on the code alone — the covered indication must be documented in the record regardless of which code is on the claim.

CMS also references Chapter 120 of the Medicare Claims Processing Manual for clinical laboratory services. Your billing team should confirm alignment with those instructions, particularly around claim submission requirements for lab tests ordered in a non-laboratory setting.

If you're unclear which codes your claims are going out under or whether they align with the covered indications, that's a conversation to have with your compliance officer now — before a post-payment audit surfaces the issue.

---